title: Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.
abstract: Mycobacterium bovis Bacille Calmette-Guérin (BCG) is one of the most widely used vaccines. Modern techniques in genome manipulation allow the construction of recombinant (r)-BCG strains that can be employed as highly immunogenic vaccines against tuberculosis (TB) with an enhanced safety profile. In addition, the development of novel procedures to cultivate BCG will allow the large-scale production of future BCG-based vaccines.
authors.affiliation: Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH-3018, Berne, Switzerland. guido.dietrich@bernabiotech.com
authors.forename: Guido
authors.initials: G
authors.lastname: Dietrich
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Viret
authors.forename: Jürgen
authors.initials: J
authors.lastname: Hess
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009163:Mycobacterium bovis / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D013678:Technology, Pharmaceutical; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
chemical_list: D001500:BCG Vaccine; D014614:Vaccines, Synthetic